Whirlwind of Risks: The MSCI World ETF’s Overconcentration Meets a Full Calendar of Stressors

URTH ETF's US exposure hits 71%, concentrated in mega-cap tech. With a hawkish Fed, overbought RSI (94.6), and index rebalancing, risks are elevated.

The iShares MSCI World ETF (URTH) has long been marketed as a one-stop, globally diversified equity vehicle. Yet fresh data from MSCI Institute, released on May 20 in its inaugural Global Investment Tracker, lays bare a stark truth: the fund is anything but global. The US now accounts for a record 71% of the developed-market capitalization tracked by the MSCI World Index, up from roughly 40% in the mid-1990s. BlackRock’s March 31 factsheet puts URTH’s US exposure at 70.98% — almost identical. The rest of the developed world is reduced to tiny supporting roles: Japan at 5.67%, the UK at 3.82%, Canada at 3.56%, France at 2.57%, and Germany at 2.27%. The MSCI World is, in effect, a US index with sprinkles.

The concentrated nature of the fund becomes even more pronounced when looking at individual names. As of April 30, NVIDIA alone was worth more than the entire equity market of every country outside the US and Japan. That chip giant is also URTH’s largest single holding at 5.30%. Combined with Apple (4.66%), Microsoft (3.27%), Amazon (2.51%), both Alphabet share classes (A: 2.09%, C: 1.75%), Broadcom (1.74%), Meta (1.56%), Tesla (1.31%), and JPMorgan Chase (1.00%), the top ten positions together swallow 25.19% of the fund’s assets. Information technology alone makes up 25.59% of the portfolio. The ETF holds over 1,300 names, but its performance is effectively steered by a handful of US mega-cap tech stocks.

That structural risk is now being aggravated by a series of near-term events that converge within a single calendar window. On May 15, Kevin Warsh became the new chair of the Federal Reserve, confirmed by the narrowest Senate majority in Fed history — 54 to 45. Warsh has signaled a desire to shrink the central bank’s balance sheet and inject more unpredictability into monetary policy. With US inflation running at 3.8% year-on-year — a three-year high — and wage growth at 3.6%, markets now price a 97% probability of no rate change at the next meeting. Bank of America and Goldman Sachs have both removed any rate cut from their 2026 forecasts. For a fund that is more than 60% US equities, that hawkish tilt is a direct headwind.

URTH’s technical picture is also flashing warning signs. The fund has posted a total return of 29.14% over the past twelve months, but its Relative Strength Index has surged to 94.6 — deep in overbought territory. Analysts warn that even minor shocks could trigger profit-taking. That risk is compounded by a double-barreled index shake-up. MSCI’s quarterly review will take effect after the close on May 29, followed by a reform of its free-float methodology on June 1. The March rebalancing was deliberately muted to avoid premature turnover, says MSCI, meaning the May adjustment demands unusually large trade volumes from physically replicating funds like URTH. Short-term volatility is expected.

Pharmaceutical tariffs add a sector-specific layer of pressure. Roughly one-tenth of URTH’s assets sit in healthcare. Starting in late July, the US will impose staggered duties on imported patent medicines: 15% on products from the EU, Japan, South Korea, and Switzerland; 10% on British drugs. FactSet analysts have already cut earnings estimates for the sector, warning of a half-percentage-point inflation pickup and compressed margins. The tariff timeline means the healthcare holdings will face a sustained earnings headwind just as the rest of the portfolio grapples with monetary tightening.

Meanwhile, BlackRock faces growing fee pressure. URTH’s expense ratio of 0.24% looks generous next to Invesco’s competing MSCI World product, which was cut to 0.05% on April 1. UBS and BNP Paribas made similar reductions earlier. BlackRock defends the premium with a tracking difference of just 0.02% — the best in its category per Morningstar — and a gold rating with five stars. That argument has held so far: net inflows into URTH reached $770 million recently, and $1.86 billion over the trailing twelve months. Total assets under management stand at roughly $8.25 billion.

A wildcard remains on the horizon. SpaceX is reportedly preparing a roadshow in early June for a potential IPO in the second half of 2026, with a mooted valuation between $1.75 trillion and $2.0 trillion and an expected issue size of over $75 billion. An offering of that magnitude would shift index weights, trigger rotation out of existing tech names, and elevate tracking error — exactly when URTH can least afford further structural turbulence.

Between the rebalancing on May 29, the methodology change on June 1, and the ex-dividend date on June 15, URTH investors face a compacted calendar with little room for comfort. The fund’s long-standing concentration risk in US mega-cap tech is no longer just a slow-burn theme — it is the backdrop against which a fast-moving series of policy, technical, and corporate events is about to play out.